|
1
|
Thirumurugan S, Muthiah KS, Lin YC, Dhawan U, Liu WC, Wang AN, Liu X, Hsiao M, Tseng CL, Chung RJ. NIR-Responsive Methotrexate-Modified Iron Selenide Nanorods for Synergistic Magnetic Hyperthermic, Photothermal, and Chemodynamic Therapy. ACS APPLIED MATERIALS & INTERFACES 2024; 16:25622-25636. [PMID: 38739745 PMCID: PMC11129116 DOI: 10.1021/acsami.3c18450] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/12/2023] [Revised: 04/20/2024] [Accepted: 04/24/2024] [Indexed: 05/16/2024]
Abstract
Breast cancer is a malignant tumor with a high mortality rate among women. Therefore, it is necessary to develop novel therapies to effectively treat this disease. In this study, iron selenide nanorods (FeSe2 NRs) were designed for use in magnetic hyperthermic, photothermal, and chemodynamic therapy (MHT/PTT/CDT) for breast cancer. To illustrate their efficacy, FeSe2 NRs were modified with the chemotherapeutic agent methotrexate (MTX). MTX-modified FeSe2 (FeSe2-MTX) exhibited excellent controlled drug release properties. Fe2+ released from FeSe2 NRs induced the release of •OH from H2O2 via a Fenton/Fenton-like reaction, enhancing the efficacy of CDT. Under alternating magnetic field (AMF) stimulation and 808 nm laser irradiation, FeSe2-MTX exerted potent hyperthermic and photothermal effects by suppressing tumor growth in a breast cancer nude mouse model. In addition, FeSe2 NRs can be used for magnetic resonance imaging in vivo by incorporating their superparamagnetic characteristics into a single nanomaterial. Overall, we presented a novel technique for the precise delivery of functional nanosystems to tumors that can enhance the efficacy of breast cancer treatment.
Collapse
Affiliation(s)
- Senthilkumar Thirumurugan
- Department
of Chemical Engineering and Biotechnology, National Taipei University of Technology (Taipei Tech), No. 1, Section 3, Zhongxiao East
Road, Taipei 10608, Taiwan
| | - Kayalvizhi Samuvel Muthiah
- Department
of Chemical Engineering and Biotechnology, National Taipei University of Technology (Taipei Tech), No. 1, Section 3, Zhongxiao East
Road, Taipei 10608, Taiwan
| | - Yu-Chien Lin
- Department
of Chemical Engineering and Biotechnology, National Taipei University of Technology (Taipei Tech), No. 1, Section 3, Zhongxiao East
Road, Taipei 10608, Taiwan
| | - Udesh Dhawan
- Centre
for the Cellular Microenvironment, Division of Biomedical Engineering,
James Watt School of Engineering, Mazumdar-Shaw Advanced Research
Centre, University of Glasgow, Glasgow G116EW, U.K.
| | - Wai-Ching Liu
- Faculty
of Science and Technology, Technological
and Higher Education Institute of Hong Kong, New Territories, Hong Kong 999077, China
| | - An-Ni Wang
- Scrona
AG, Grubenstrasse 9, 8045 Zürich, Switzerland
| | - Xinke Liu
- College
of Materials Science and Engineering, Chinese Engineering and Research
Institute of Microelectronics, Shenzhen
University, Shenzhen 518060, China
- Department
of Electrical and Computer Engineering, National University of Singapore, Singapore 117583, Singapore
| | - Michael Hsiao
- Genomics
Research Center, Academia Sinica, Taipei 115, Taiwan
- Department
and Graduate Institute of Veterinary Medicine, School of Veterinary
Medicine, National Taiwan University, Taipei 10617, Taiwan
| | - Ching-Li Tseng
- Graduate
Institute of Biomedical Materials and Tissue Engineering, College
of Biomedical Engineering, Taipei Medical
University, Taipei 11031, Taiwan
- International
Ph.D. Program in Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei 11031, Taiwan
- Research
Center of Biomedical Device, College of Biomedical Engineering, Taipei Medical University, Taipei 11031, Taiwan
- International
Ph.D. Program in Cell Therapy and Regenerative Medicine, College of
Medicine, Taipei Medical University, Taipei 11031, Taiwan
| | - Ren-Jei Chung
- Department
of Chemical Engineering and Biotechnology, National Taipei University of Technology (Taipei Tech), No. 1, Section 3, Zhongxiao East
Road, Taipei 10608, Taiwan
- High-Value
Biomaterials Research and Commercialization Center, National Taipei University of Technology (Taipei Tech), Taipei 10608, Taiwan
| |
Collapse
|
|
2
|
Bhattacharya S, Prajapati BG, Ali N, Mohany M, Aboul-Soud MAM, Khan R. Therapeutic Potential of Methotrexate-Loaded Superparamagnetic Iron Oxide Nanoparticles Coated with Poly(lactic- co-glycolic acid) and Polyethylene Glycol against Breast Cancer: Development, Characterization, and Comprehensive In Vitro Investigation. ACS OMEGA 2023; 8:27634-27649. [PMID: 37546601 PMCID: PMC10398847 DOI: 10.1021/acsomega.3c03430] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/17/2023] [Accepted: 07/11/2023] [Indexed: 08/08/2023]
Abstract
Novel superparamagnetic iron oxide nanoparticles (SPIONs) of Methotrexate (MTX) were developed using supercritical liquid technology and optimized with a Box-Behnken design in order to assess its potential as a candidate for the treatment of breast cancer. MTX-SPIONs coated with poly(lactic-co-glycolic acid)-polyethylene glycol 400 had an aggregate size of 500 nm and an encapsulation efficiency of 46.8 ± 3.9%. The Fourier-transformed infrared spectroscopy analysis revealed a shift in the main bands due to intermolecular hydrogen bonds, whereas the differential scanning calorimetry analysis revealed the absence of the MTX melting endotherm, indicating complete encapsulation with oxide nanoparticles. The zeta potential results indicated a value of 4.98 mV, whereas the in vitro release study revealed an initial burst release followed by a considerable release of 35.1 ± 2.78% after 12 h. Using flow cytometry, control, MTX, and MTX-SPIONs were evaluated for apoptosis, with MTX-SPIONs exhibiting greater apoptosis than the control group and MTX. In addition, MTX-SPIONs inhibited cell division and content organization while substantially increasing the proportion of cells in the G1 and G2 phases relative to the control group. MTX-SPIONs exhibited prolonged anticancer effects against MCF-7 cell lines compared to MTX alone, indicating that SPION-delivered chemotherapeutics may increase cytotoxicity. The medication was stable with low encapsulated drug loss, suggesting that the supercritical liquid technology-based method is a promising way for generating drug-polymer magnetic composite nanoparticles for cancer treatment.
Collapse
Affiliation(s)
- Sankha Bhattacharya
- School
of Pharmacy & Technology Management, SVKM’S NMIMS Deemed-to-be University, Shirpur, Maharashtra 425405, India
| | - Bhupendra G Prajapati
- Shree
S. K. Patel College of Pharmaceutical Education and Research, Ganpat University, Kherva 384012, India
| | - Nemat Ali
- Department
of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia
| | - Mohamed Mohany
- Department
of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia
| | - Mourad A. M. Aboul-Soud
- Department
of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud University, Riyadh 11433, Saudi Arabia
| | - Rehan Khan
- Public
Health Research Institute, Rutgers, New
Jersey Medical School, Newark, New Jersey 07103; United States
| |
Collapse
|
|
3
|
Common Shortcomings in Study on Radiopharmaceutical Design Research: A Case Study of 99mTc-Labelled Methotrexate. Molecules 2021; 26:molecules26195862. [PMID: 34641406 PMCID: PMC8510358 DOI: 10.3390/molecules26195862] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2021] [Revised: 09/24/2021] [Accepted: 09/24/2021] [Indexed: 11/22/2022] Open
Abstract
The aim of the work carried out was to draw attention to shortcomings that often appear at the stage of designing new radiopharmaceuticals. Based on a case study of 99mTc-labelled methotrexate, this article describes frequent mistakes or misconceptions present not only in the referenced studies, but also in numerous radiopharmaceutical studies. The recommendations provided in this article highlight fundamental aspects of the credibility of radiopharmaceutical scientific research leading to the reliable results.
Collapse
|